Le Lézard
Classified in: Health
Subject: CCA

CVS Health to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call


WOONSOCKET, R.I., Jan. 12, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, February 7, 2024, at 8:00 a.m. ET to discuss fourth quarter and full year 2023 financial results.

An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.

About CVS Health
CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues ? including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individuals with their health ? whether that's managing health conditions, staying compliant with their medications or accessing affordable health services in the most convenient ways. Our goal is to create seamless connections across the health care system, simplifying the experience and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

CVS Health logo (PRNewsFoto/CVS Health)

 

SOURCE CVS Health Corporation


These press releases may also interest you

at 03:12
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A....

at 03:05
PathAI Announces Early Access Program to Drive Adoption of AISight Image Management System in Anatomic Pathology Laboratories Across Mainland Europe
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for...

at 03:00
Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its...

at 03:00
YGION Biomedical announces ?15 Million Series A Financing to develop Individualized Cancer Immunotherapies
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A financing round of ?15 million from an Austrian private trust. The proceeds will be used to further...

at 02:59
Biometric Cards Market to Reach $89 Billion Globally by 2032 at 22.4% CAGR: Allied Market Research
Allied Market Research has recently published a report, titled, "Biometric Cards Market Size, Share, Competitive Landscape and Trend Analysis...

at 02:05
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and...

More news about Health...


News published on and distributed by: